code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic doxazosin mesylate 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound.

mesylate, a quinazoline compound sold by Pfizer under doxazosin mesylate brand names Cardura® and doxazosin mesylate , is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form doxazosin mesylate doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood doxazosin mesylate and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a doxazosin mesylate release form doxazosin mesylate doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign doxazosin mesylate hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which inhibits the binding doxazosin mesylate norepinephrine to alpha.

smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.[edit].